FINNENCE ▪ THE WIRE FILE
THE WIRE · № 72980
Company■ Unclear/unknown
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES3
ENTITIES1
STORY SIZE3 RECORDS
FIRST SEEN2026-10-09 12:00 UTC
LAST UPDATE2026-10-09 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Itepekimab COPD Phase 3 results matter for Sanofi's respiratory pipeline.
Large COPD trial data informs Sanofi pipeline outlook
CATALYST TO WATCH
Full data disclosure and regulatory submission
MAIN RISK
Results direction not specified in the posting
FULL DISPATCH
Sponsor: Sanofi; Status: Completed; Conditions: Chronic Obstructive Pulmonary Disease; Interventions: Itepekimab SAR440340, Placebo; Enrollment: 1234 (actual); First posted: 2021-02-12; Results posted: 2026-10-09; NCT: NCT04751487
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 3 TIMES · FIRST 2026-10-09 12:00 UTC · LAST 2026-10-09 12:00 UTC2026-10-09 12:00 UTCCompanyPhase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — SanofiCURRENT RECORD
2026-10-09 12:00 UTCCompanyPhase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche
2026-10-09 12:00 UTCCompanyPhase 3 results posted: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Hoffmann-La Roche
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Hoffmann-La Roche2026-10-09 12:00 UTC
Phase 3 results posted: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Hoffmann-La Roche2026-10-09 12:00 UTC
→CORRELATIONshares Healthcare
CTY IPO News - RNA interference biotech City Therapeutics sets terms for $175 million IPO2026-10-09 12:44 UTC
CTY IPO News - RNA interference biotech City Therapeutics sets terms for $175 million IPO2026-10-09 12:44 UTC
→CORRELATIONshares Healthcare
SciBase's rights issue registered, conversion of BTA into shares2026-10-09 13:19 UTC
SciBase's rights issue registered, conversion of BTA into shares2026-10-09 13:19 UTC
→CORRELATIONshares Healthcare
Insurance Leaders Convene to Shape the Future of Claims and Underwriting in the Age of AI2026-10-09 13:34 UTC
Insurance Leaders Convene to Shape the Future of Claims and Underwriting in the Age of AI2026-10-09 13:34 UTC
←CORRELATIONshares Healthcare
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis2026-10-09 11:00 UTC
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis2026-10-09 11:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.